HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 529-540

  Díaz Delfín, Julieta ^a   Domingo, Pere ^b,c   Wabitsch, Martin ^d   Giralt, Marta ^a   Villarroya, Francesc ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; GLUCOSE; GLUCOSE TRANSPORTER 4; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PARTHENOLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESVERATROL; ROSIGLITAZONE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADIPOCYTE; ADIPOGENESIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MARKER GENE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROADIPOCYTE;

ADIPOCYTES; ADIPOGENESIS; CYTOKINES; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INFLAMMATION; SESQUITERPENES; STILBENES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861695648     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2021     Document Type: Article

References (50)

1. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010; 16:218-229.
2. Villarroya F, Domingo P, Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (Lond) 2007; 31:1763-1776. (Pubitemid 350174633)
3. Boyd MA, Dixit NM, Siangphoe U, et al. Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). J Infect Dis 2006; 194:1319-1322. (Pubitemid 44630978)
4. Flint OP, Noor MA, Hruz PW, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 2009; 37:65-77.
5. Visnegarwala F, Raghavan SS, Mullin CM, et al. Sex differences in the associations of HIV disease characteristics and body composition in antiretroviral-naive persons. Am J Clin Nutr 2005; 82:850-856. (Pubitemid 43779700)
6. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy. Antivir Ther 2006; 11:729-740. (Pubitemid 44497168)
7. Hazan U, Romero IA, Cancello R, et al. Human adipose cells express CD4, CXCR4, and CCR5 receptors: a new target cell type for the immunodeficiency virus-1? FASEB J 2002; 16:1254-1256.
8. Dupin N, Buffet M, Marcelin AG, et al. HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. AIDS 2002; 16:2419-2424. (Pubitemid 35471689)
9. Munier S, Borjabad A, Lemaire M, Mariot V, Hazan U. In vitro infection of human primary adipose cells with HIV-1: a reassessment. AIDS 2003; 17:2537-2539. (Pubitemid 38393329)
10. Maurin T, Saillan-Barreau C, Cousin B, Casteilla L, Doglio A, Pénicaud L. Tumor necrosis factor-alpha stimulates HIV-1 production in primary culture of human adipocytes. Exp Cell Res 2005; 304:544-551. (Pubitemid 40321130)
11. Shrivastav S, Kino T, Cunningham T, et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferatoractivated receptor-γ and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol 2008; 22:234-247. (Pubitemid 351185928)
12. Romani B, Engelbrecht S, Glashoff RH. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol 2010; 91:1-12.
13. Laspia MF, Rice AP, Mathews MB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989; 59:283-292. (Pubitemid 19264374)
14. Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67:277-287. (Pubitemid 23002988)
15. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11:1421-1431. (Pubitemid 27421173)
16. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375:497-500.
17. Xiao H, Neuveut C, Tiffany HL, et al. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A 2000; 97:11466-11471.
18. Ju SM, Song HY, Lee JA, Lee SJ, Choi SY, Park J. Extracellular HIV-1 Tat up-regulates expression of matrix metalloproteinase-9 via a MAPK-NF-kappaB dependent pathway in human astrocytes. Exp Mol Med 2009; 41:86-93.
19. Bennasser Y, Bahraoui E. HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-βII and -δ. FASEB J 2002; 16:546-554. (Pubitemid 34273238)
20. Chen P, Mayne M, Power C, Nath A. The Tat protein of HIV-1 induces tumor necrosis factor-a production: implications for HIV-1-associated neurological diseases. J Biol Chem 1997; 272:22385-22388. (Pubitemid 27386042)
21. Cupp C, Taylor JP, Khalili K, Amini S. Evidence for stimulation of the transforming growth factor beta1 promoter by HIV-1 Tat in cells derived from CNS. Oncogene 1993; 8:2231-2236. (Pubitemid 23226957)
22. Li JC, Yim HC, Lau AS. Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection. AIDS 2010; 24:1609-1623.
23. Wabitsch M, Brenner RE, Melzner I, et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord 2001; 25:8-15. (Pubitemid 32142378)
24. Campbell GR, Loret EP. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology 2009; 6:50.
25. Hayashi K, Pu H, Andras IE, et al. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 2006; 26:1052-1065. (Pubitemid 44134076)
26. Toborek M, Lee YW, Pu H, et al. HIV-Tat protein induces oxidative and infl ammatory pathways in brain endothelium. J Neurochem 2003; 84:169-179. (Pubitemid 36182077)
27. András IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 2003; 74:255-265. (Pubitemid 37193712)
28. Lee YW, Eum SY, Nath A, Toborek M. Estrogen-mediated protection against HIV Tat protein-induced infl ammatory pathways in human vascular endothelial cells. Cardiovasc Res 2004; 63:139-148. (Pubitemid 38759818)
29. Nath A, Conant K, Chen P, Scott C, Major EO. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 1999; 274:17098-17102.
30. Do MS, Jeong HS, Choi BH, et al. Inflammatory gene expression patterns revealed by DNA microarray analysis in TNF-alpha-treated SGBS human adipocytes. Yonsei Med J 2006; 47:729-736.
31. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953-12956.
32. Yoshizaki T, Milne JC, Imamura T, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009; 29:1363-1374.
33. Howitz KT, Bitterman HY, Cohen DW, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191-196. (Pubitemid 37150899)
34. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001; 8:759-766. (Pubitemid 32752455)
35. Mayol K, Munier S, Beck A, Verrier B, Guillon C. Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity. Vaccine 2007; 25:6047-6060. (Pubitemid 47082461)
36. Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286:E261-E271. (Pubitemid 38140318)
37. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci 2004; 25:331-336. (Pubitemid 38692426)
38. Gougeon ML, Pénicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004; 9:161-177. (Pubitemid 38560209)
39. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127:1109-1122. (Pubitemid 44894520)
40. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337-342. (Pubitemid 44764104)
41. Touzet O, Philips A. Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation. AIDS 2010; 24:1437-1447.
42. Pagans S, Pedal A, North BJ, et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 2005; 3:e41.
43. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429:771-776. (Pubitemid 38833129)
44. Floyd ZE, Wang ZQ, Kilroy G, Cefalu WT. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol. Metabolism 2008; 57 Suppl 1:S32-S38. (Pubitemid 351814704)
45. Lee EO, Kim SE, Park HK, et al. Extracellular HIV-1 Tat upregulates TNF-a dependent MCP-1/CCL2 production via activation of ERK1/2 pathway in rat hippocampal slice cultures: inhibition by resveratrol, a polyphenolic phytostilbene. Exp Neurol 2011; 229:399-408.
46. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16:225-260. (Pubitemid 28183365)
47. Ott M, Lovett JL, Mueller L, Verdin E. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kB factors. J Immunol 1998; 160:2872-2880. (Pubitemid 28136742)
48. Conant K, Ma M, Nath A, Major EO. Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-kB binding and protein kinase C activity in primary human astrocytes. J Virol 1996; 70:1384-1389.
49. Lee YW, Hirani AA, Kyprianou N, Toborek M. Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells. Inflamm Res 2005; 54:380-389.
50. Gandhi N, Saiyed Z, Thangavel S, Rodriguez J, Rao KV, Nair MP. Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses 2009; 25:691-699.